AUA

“The main advantages with regard to the Zenflow Spring System are that there's no piercing, there's no trauma, and there's no heat involved with the treatment,” says Peter Chin, MD.

To examine the disparities of ED diagnosis and referral, Denise Asafu-Adjei, MD, MPH, and a team of investigators conducted a study involving 2 outpatient urology settings who serve communities with varying demographics.

"Although the effects of a plant-based diet on the cardiovascular system and endocrine system are well-documented and very well-studied, the effect on erectile function [is not fully understood]," says Ruben Blachman-Braun, MD.

Senior author Peter N. Schlegel, MD, FACS, recently presented updates to the AUA/ASRM guideline for the diagnosis and treatment of infertility in men at the 2021 AUA Annual Meeting.

“[Rezum] does give men another option, and so I think that's…really what we're focusing on here: giving the option to avoid general anesthesia and to avoid a bigger surgery,” says Michael A. Palese, MD.

“We're getting close, and we hope to have things concluding here soon and then to be able to offer some of these technologies on a on a wider scale,” says Mathew D. Sorensen, MD, MS, FACS.

“I’m looking forward to comparisons of minimally invasive surgery versus medical therapy, that is, at this point, untapped. It's something which we think we have insight into, but we really don't have good data,” says Kevin T. McVary, MD.

In a study presented at the 2021 AUA Annual Meeting, Karim Chamie, MD, and coauthors further examine the long-term results of UGN-101 for patients with LG UTUC given the favorable outcomes of the initial OLYMPUS trial.

Mathew D. Sorensen, MD, MS, FACS, and a team of investigators recently assessed the efficacy and safety of ultrasonic propulsion treatment on patients with kidney stones.

“We were able to show that there was a very…clinically significant decrease in the rate of UTIs in the vaccinated group, preventing UTIs in almost 60% of vaccinated patients,” says J. Curtis Nickel, MD.

In a recent study presented at the 2021 AUA Annual Meeting, Naeem Bhojani, MD, FRCSC, David-Dan Nguyen, and co-authors reported the favorable 3-year results of ongoing Aquablation research specifically involving patients with large prostates.

“Figuring out a good, comfortable way to bring that [ED] conversation up…will really pay dividends in other parts of the health care system. It will also allow more people to appropriately get funneled to urology to better address it,” says Denise Asafu-Adjei, MD, MPH.

“[BPH treatment] has to be individualized to the motivations of the patient, and also what I call his "phenotype.” How big is his prostate? How bad is this problem? And what is his tolerance for side effects?” says Kevin T. McVary, MD.

In a recent study, presented at the 2021 AUA Annual Meeting, Peter Chin, MD, and co-authors assessed the efficacy of the investigational Zenflow Spring System in treating patients with BPH.

"These data are growing rapidly, and awareness of where we stand right now and the potential that could change as well in the future with new data is important for the practicing urologist,” says Peter N. Schlegel, MD, FACS.

“More research needs to be done, but I think this is something that gets the conversation started,” says Tony Chen, MD.

An aggressive treatment, such as bladder removal, may be necessary in patients with early stage micropapillary bladder cancer because the disease may behave more like late-stage conventional urothelial carcinoma.

"This particular study comes from our human randomized trial that we hope will be the final step before FDA approval for the technology,” says Mathew D. Sorensen, MD, MS, FACS.

In this interview, Kevin Zorn, MD, discusses 3-year results from a study of robot-assisted Aquablation procedures in treating men with large prostates.

“We have the rising spectra of national and international antibiotic resistance, which is becoming a huge international medical issue,” says J. Curtis Nickel, MD.

"The challenges involved in medical stone prevention are first, making the diagnosis with current protocols," says Glenn M. Preminger, MD.

“BCG-unresponsive non–muscle-invasive bladder cancer is really [an] evolving space with a lot of uncertainty,” says Kelly L. Stratton, MD.

“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.

"The take-home message is that Optilume is safe, and that it's superior to standard DVIU or dilation for the treatment of recurrent anterior urethral strictures that are less than 3 cm in length," says Sean P. Elliott, MD, MS, FACS.

The MV140 vaccine "will be a game changer for women's health in the future," says J. Curtis Nickel, MD.

“The notable finding was that the combination was well tolerated,” says Kelly L. Stratton, MD.

“Although numbers of participants with certain disease risk features were small, the DFS benefit was consistent across subgroups,” said lead study author Toni K. Choueiri, MD.

Phase 1/2 data showed that large surface area microparticle docetaxel is safe with early signs of clinical activity in patients with high-risk non–muscle invasive bladder cancer.

The minimally invasive single port robot-assisted radical prostatectomy led to high postoperative continence rates and significant improvements in IPSS and PVR measures.

The mitomycin-containing reverse thermal gel UGN-101 (Jelmyto) produced durable responses in patients with low-grade upper tract urothelial carcinoma.